SecBot SecBot
8-K ·Filed Apr 20, 2026

RCUS

Arcus Biosciences, Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed7mo ago SEC0001724521-26-000021
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Traders should anticipate downward pressure on RCUS shares due to the failure of a pivotal Phase 3 trial and reduced strategic partnership optionality with Gilead. Monitor upcoming presentations for detailed data from the futility analysis and assess implications for other TIGIT-targeting therapies in development.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.74
T+0 close · Apr 20, 2026 · via day close
Latest settled
+23.22%
T+60 · $28.02
Vs SPY
+16.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $22.74entry
  2. T+1 · 7mo ago +7.83%α +8.48% · $24.52
  3. T+5 · 7mo ago +9.72%α +8.81% · $24.95
  4. T+20 · 6mo ago +2.90%α −1.30% · $23.40
  5. T+60 · 4mo ago +23.22%α +16.44% · $28.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer due to futility, based on an independent data monitoring committee's recommendation. Additionally, Gilead will not extend its option rights to Arcus's early-stage pipeline programs beyond July 14, 2026, retaining only limited existing options.

Key Facts

  • Phase 3 STAR-121 study evaluating domvanalimab + zimberelimab + chemo vs. pembrolizumab + chemo in first-line metastatic NSCLC discontinued due to futility
  • Decision based on pre-planned futility analysis by Independent Data Monitoring Committee (IDMC); safety not assessed at this stage
  • Exploratory endpoint showed zimberelimab + chemo performed consistently with pembrolizumab + chemo on overall survival
  • Phase 2 EDGE-Lung study also being discontinued
  • Gilead will not make option continuation payment, ending its rights to early-stage programs (CCR6, CD89, CD40L) after July 14, 2026
  • Gilead retains time-limited options to AB801, AB598, AB102, and an investigational TNF inhibitor
  • Arcus regains full rights to casdatifan development program outside of Taiho-licensed territories

Financial Impact

Significant negative impact expected due to loss of late-stage oncology program and reduced partnership value with Gilead; no specific financial figures disclosed

pipeline valuepartnership revenueR&D valuationmarket sentiment

Risk Factors

  • Further devaluation of Arcus's immuno-oncology pipeline
  • Reduced likelihood of near-term partnership or acquisition interest
  • Potential for additional trial discontinuations in related programs

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001724521-26-000021
Document: 0001724521-26-000021-index.html0001724521-26-000021
Document: 0001724521-26-000021.txt0001724521-26-000021

Track record

13 reports on RCUS

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 Now $16.86 −0.53% settles Nov 23
  2. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $18.95 to $16.86 Now $16.86 −11.03% ▼ −11.03% −9.34% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 Now $16.86 −4.69% ▲ +0.45% −2.84% vs SPY
  4. Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 Now $16.86 +5.07% ▼ −2.42% −3.68% vs SPY
  5. Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 Now $16.86 +9.06% ▲ +1.89% +1.33% vs SPY
  6. Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 Now $16.86 +12.91% ▲ +3.87% +4.58% vs SPY
  7. Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 Now $16.86 −12.91% ▼ −3.87% −4.58% vs SPY
  8. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 Now $16.86 −29.01% ▼ −23.62% −23.70% vs SPY
  9. Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 Now $16.86 −41.70% ▼ −7.88% −7.32% vs SPY
  10. Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 Now $16.86 −36.66% ▼ −7.79% −7.85% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026